Revolution Medicines and Moderna prove that high-risk bets on undruggable targets can finally work - here's what it means for biotech investors and pharma execs.

Earnings surge at onshore firms, yet investors punish tech as AI spending shifts from promise to expense.

Robert Kiyosaki says he owes US$1.2 billion; in China, burned property investors are wrestling with awe and bitterness.

Investors wanted more details on Tesla's robotaxi plans, but the Cybercab update left them wanting, triggering a sell-off.

A stronger yen is threatening the cheap-funding trade that global investors have leaned on for years - here's what an unwind would hit first.

Fidelity's second-quarter report shows a record number of 401(k) millionaires and steady high balances - a signal of long-term discipline amid persistent economic anxiety.

Star Market profits quadruple on chip demand while the broader market lags, exposing a K-shaped recovery that investors can't ignore.

The data center firm has no operating facilities and no revenue, yet its future hinges on OpenAI contracts. Here's what that means for investors.

Harrison Street's Mike Gordon explains why funding cuts and enrollment trends are making specialization the new deal-breaker for student housing investors.

As the GLP-1 market heats up, Novo Nordisk's chief insists Wall Street is missing the full value of its weight-loss and diabetes portfolio.

Three global banks host conferences in the Chinese tech hub, signaling a shift in capital flows toward the country's advanced manufacturing and AI sectors.

The fast-fashion giant finally listed in Hong Kong on Tuesday, but investors greeted it with a sell-off. Here's what the debut signals for the company and the broader market.